Ignite Creation Date:
2024-05-06 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03512197
Status:
COMPLETED
Last Update Posted:
2023-08-21
First Post:
2018-03-26
Brief Title:
A Global Study of the Efficacy and Safety of Midostaurin Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative FLT3-MN Acute Myeloid Leukemia AML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia AML |
Keywords:
| Name | View |
|---|---|
| minimal residual disease | View |
| Newly diagnosed FLT3-mutation negative | View |
| PKC412 | View |
| midostaurin | View |
| cytarabine | View |
| daunorubicin | View |
| idarubicin | View |
| acute myeloid leukemia | View |
| AML | View |
| FLT3-MN SR005 | View |
| combination treatment | View |
| induction failure | View |
| event free survival | View |
| EFS | View |